Matinas Biopharma(MTNB)

Focus: Matinas Biopharma is a public-stage pharmaceutical company focused on dyslipidemia and cardiovascular treatments, with a diversified pipeline spanning fungal infections and metabolic diseases. The company operates at a modest scale with minimal revenue generation and significant R&D investment.

Cardiovascular Metabolic Diseases

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Matinas Biopharma

AI assessmentNot Hiring

No open roles listed right now. Follow Matinas Biopharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$1M

Pipeline & Clinical Trials

FungiScope - A Global Emerging Fungal Infection Registry

Invasive Fungal Disease

N/A

Encochleated Amphotericin B

Cryptococcal Infections

Phase 1/2

Clinical Trials (1)

Help build intelligence for Matinas Biopharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to early-stage, high-risk/high-reward programs including Phase 3 candidates in hypertriglyceridemia and cryptococcal meningitis
Diversified pipeline across cardiovascular, metabolic, and infectious disease indicates broad technical skill-building opportunities
Public company status with active clinical programs provides exposure to regulatory milestones and investor relations dynamics

Watch Out For

Severe financial constraints: $5M cash position (FY 2025) against $11M R&D spend and $24M net loss signals potential runway concerns
Minimal commercial traction: only $1M revenue in FY 2024 and zero active job openings indicate organizational stress and limited career advancement velocity
Early-stage pipeline heavy on Phase 2 programs with only 2 Phase 3 candidates; no approved products means no established market presence or revenue base

Generated by Claude from Matinas Biopharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

NCT03196921Efficacy and Safety of Oral Encochleated Amphotericin B for the Treatment of Cryptococcal Infection

Phase 1/2

Drug Omega 3

Hypertriglyceridemia

Phase 1/2

Clinical Trials (1)

NCT02310022A PK and PD Study of Two Formulations of Omega-3 One Gram Capsules

Phase 1/2

MAT2203

Cryptococcal Meningitis

Phase 1/2

Clinical Trials (1)

NCT04031833Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)

Phase 1/2

Omega 3 pentaenoic acid

Hypertriglyceridemia

Phase 2

Clinical Trials (1)

NCT04177680Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia

Phase 2

Oral Encochleated Amphotericin B

Vulvovaginitis

Phase 2

Clinical Trials (1)

NCT02971007Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)

Phase 2

Oral Encochleated Amphotericin B

Vulvovaginal Candidiases

Phase 2

Clinical Trials (1)

NCT03167957Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis

Phase 2

Amphotericin B

Candidiasis, Chronic Mucocutaneous

Phase 2

Clinical Trials (1)

NCT02629419CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis

Phase 2

Oral Encochleated Amphotericin B

Acute Myeloid Leukemia

Phase 2

Clinical Trials (1)

NCT03187691Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia

Phase 2

MAT2203

Cryptococcal Meningitis

Phase 3

Clinical Trials (1)

NCT05541107Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3

Phase 3

Placebo

Severe Hypertriglyceridemia

Phase 3

Clinical Trials (1)

NCT04662528Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL